Key Points {#FPar1}
==========

Recent data have highlighted how considerable further improvement in outcomes in apparently stable patients with heart failure (HF) is possible if primary care physicians (PCPs) optimize delivery of care.Although no simple means exist for PCPs to predict when a seemingly stable patient will decompensate, use of novel pharmacological agents may prevent the progression of HF.This article outlines HF-management recommendations for PCPs, with a focus on patients with stable but progressive disease.

Introduction {#Sec1}
============

Heart failure (HF) is a clinical syndrome caused by structural or functional abnormalities of the heart, resulting in a reduction in cardiac output or elevation of ventricular filling pressures at rest or during exercise. The major manifestations of HF are breathlessness, decreased exercise tolerance, and fatigue, which may be accompanied by signs of fluid retention, including peripheral edema, elevated jugular venous pressure, and crackles in the lungs.

The prevalence of HF increases with age \[[@CR1]\]. However, in the last several decades, advances in HF treatment have led to improvements in survival, both in clinical trials and in the community \[[@CR2]--[@CR4]\]. These decreases in mortality extend to very elderly patients (aged \> 80 years) who have been hospitalized for HF \[[@CR5]\].

Primary care physicians (PCPs) play an important role in improving outcomes in patients with HF, principally by implementing guideline-directed evaluation and management (GDEM) shown to reduce the risks of mortality and HF hospitalization \[[@CR2], [@CR3]\]. In addition, PCPs play an active role in preventing HF-related hospital readmissions in accordance with the US Affordable Care Act's Hospital Readmission Reduction Program, which penalizes hospitals with above-average 30-day readmission rates for Medicare patients \[[@CR6]\].

Despite recent improvements in mortality rates among patients with HF, the 5-year survival rates remain at about 50% \[[@CR7]\]. Furthermore, as the US population ages, the healthcare burden of HF is expected to increase dramatically. Data from a 2015 report noted that HF affects more than 5 million Americans, and annual healthcare costs are more than \$US30 billion \[[@CR7]\]. By 2030, an estimated 8.5 million adults in the USA will have HF, with annual costs of \$US70 billion \[[@CR7], [@CR8]\]. Thus, significant treatment advances are needed to further improve outcomes. Improvements in management are especially needed for the large population of patients with New York Heart Association (NYHA) class II or III functional status, the largest population of patients with HF. These patients are often perceived to have more stable disease. However, sudden cardiac death remains the leading cause of mortality in these patients, and they account for the majority of HF-related hospitalizations and deaths \[[@CR9]\].

Given their increasing role in managing HF, PCPs are in a position to work with patients to improve clinical outcomes. Recent data have highlighted how considerable further improvement in outcomes in apparently stable patients with HF is possible if PCPs optimize their care. This article outlines management recommendations, with a focus on patients with stable but progressive HF.

Classification and Management of the Stages of HF {#Sec2}
-------------------------------------------------

Historically, HF was dichotomized based on measurement of the left ventricular (LV) ejection fraction (EF) \[[@CR2], [@CR10]\]. Patients with LVEF ≥ 50% were considered to have HF with normal or preserved EF (HFpEF) and those with LVEF ≤ 40%, HF with reduced EF (HFrEF) \[[@CR2], [@CR10]\]. This left patients with an LVEF in the range of 40--49% in a "grey area," which has been varyingly defined \[[@CR10]\]. Most recently, the 2016 European Society of Cardiology HF guidelines defined such patients as having HF with mid-range EF (HFmrEF) \[[@CR10]\]. However---as discussed later in this article---for the sake of management, patients with HFpEF and HFmrEF are considered collectively. Epidemiological studies suggest that approximately 50% of the total HF population have HFrEF and the remainder have HFpEF and HFmrEF \[[@CR2], [@CR11]\]. Therapeutic strategies for the management of HF differ based on EF classification because the response to therapy varies between the two groups \[[@CR2]\]. Moreover, recommendations for the use of pharmacological GDEM have been more extensively developed for HFrEF than for HFpEF, because clinical trials have demonstrated benefits with such therapies in patients with HFrEF but not in patients with HFpEF \[[@CR12]\]. As such, this review focuses primarily on HFrEF management. GDEM for patients with HFpEF focuses primarily on managing symptoms and addressing risk factors and comorbidities for disease progression \[[@CR2]\].

In 2009, the American College of Cardiology (ACC)/American Heart Association (AHA) further classified HF into stages that emphasized the progressive nature of the disease, from risk factors to development of structural heart disease. The stages complement the NYHA functional classifications that focus on limitation of exercise capacity and the symptomatic status of the patient. At each stage of the new classification, management is aimed at preventing the development of the next stage.

Stage A patients have risk factors for the development of HF but do not have structural or functional heart disease and are asymptomatic. Management of risk factors prevents the development of HF in patients at this stage. For example, long-term treatment of hypertension has been shown to reduce the risk of developing HF by approximately 50% \[[@CR2], [@CR13]--[@CR17]\]. Similarly, treatment of hyperlipidemia with statin therapy reduces the risk of developing cardiovascular disease (CVD), including HF \[[@CR18]\]. In addition, insulin resistance has been shown to increase the risk of developing HF \[[@CR19]--[@CR23]\], and glycated hemoglobin (HbA~1c~) concentration ≥ 10.5% was associated with increased risk for developing HF compared with HbA~1c~ concentration \< 6.5% \[hazard ratio (HR) 3.98; 95% confidence interval (CI) 2.23--7.14\] \[[@CR22]\]. Although hyperglycemia contributes to the development of HF, its treatment as a risk factor for CVD has been controversial because some hypoglycemic medications have been shown to increase the risk of cardiovascular events \[[@CR24]\]; however, recent data indicate that sodium--glucose cotransporter-2 (SGLT2) inhibitors reduced the rate of cardiovascular outcomes, including HF, and may be considered to treat hyperglycemia in patients at high risk of CVD \[[@CR25]\]. In particular, an analysis of data from the EMPA-REG OUTCOMES (Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes; ClinicalTrials.gov number, NCT01131676) trial has shown that empagliflozin, an SGLT2 inhibitor, is associated with a reduced risk for HF-related hospitalization or death compared with placebo (HR 0.61; 95% CI 0.47--0.79; *P *\< 0.001) \[[@CR26]\]. Thus, the effective management of these risk factors received a recommendation \[class of recommendation (COR) I, level of evidence (LOE) A\] to prevent the development of HF \[[@CR2]\]. Both pharmacological treatments, such as SGLT2 inhibitors for patients with diabetes mellitus, and lifestyle modifications, including sodium restriction in patients with hypertension, are appropriate strategies to reduce the risk of developing HF at this stage \[[@CR2]\].

Stage B patients are those who have already developed structural heart disease, such as myocardial infarction, LV dysfunction or LV hypertrophy, but are asymptomatic \[[@CR2]\]. These stage B patients with asymptomatic LV dysfunction (ASLVD) are at an increased risk of experiencing a CV event (HR 3.32; 95% CI 1.98--5.58; *P *\< 0.0001) and mortality (HR 3.47; 95% CI 2.03--5.94; *P *\< 0.0001) \[[@CR27]\]. To reduce the risk of morbidity and mortality and prevent progression to symptomatic HF in patients with ASLVD, the ACC Foundation (ACCF)/AHA Guideline for the Management of Heart Failure provides a class I (LOE A) recommendation for the use of the angiotensin-converting enzyme inhibitor (ACEI) enalapril \[[@CR2]\]. This recommendation is based on the results of the SOLVD (Studies of Left Ventricular Dysfunction) prevention trial, which reported that treatment with enalapril compared with placebo reduced the risk of death or hospitalization for congestive HF by 20% (95% CI 9--30; *P *\< 0.001) \[[@CR28]\]. Furthermore, an analysis of the 15-year post-trial follow-up data found that the beneficial effects of initial randomization to enalapril therapy, compared with placebo, continued to be seen throughout this period, with an overall absolute mortality risk reduction (ARR) of 6.5% (*P* = 0.01) \[[@CR29]\]. These results underscore the importance of the early initiation of therapy and suggest that delaying treatment in patients with LV systolic dysfunction increases their risk of morbidity and mortality. Finally, myocardial revascularization to correct ischemia has been shown to be associated with better clinical prognosis \[[@CR30], [@CR31]\]. Screening with non-invasive imaging to detect myocardial ischemia is recommended for patients with new-onset HFrEF and coronary artery disease without angina, unless the patient is not eligible for revascularization of any kind (COR IIA, LOE C) \[[@CR2]\].

Stage C patients have structural heart disease with prior or current symptoms of HF \[[@CR2]\]. Before the recent approval of the two new HF therapies, ivabradine and sacubitril/valsartan, the 2013 ACCF/AHA guidelines recommended that patients with stage C HFrEF receive GDEM, in addition to management of comorbidities, to reduce their risk of disease progression (COR I, LOE A) \[[@CR2]\]. The mainstay of GDEM for patients with stage C disease at that time included the use of recommended doses of ACEI---and if not tolerated, angiotensin receptor blocker (ARB) therapy (COR I, LOE A)---along with adequate doses of beta-blocker therapy with bisoprolol, carvedilol, or sustained-release metoprolol succinate (COR I, LOE A) to reduce the risk of morbidity and mortality \[[@CR2]\]. To further reduce morbidity and mortality, aldosterone receptor antagonists are recommended (COR I, LOE A) on top of ACEI/ARB and beta-blocker therapy in patients with NYHA class II--IV HFrEF, provided adequate renal function and potassium concentration \< 5 mEq/dl \[[@CR2]\]. In symptomatic African American patients with NYHA class III--IV HFrEF already receiving optimal doses of ACEI/ARB and beta-blocker therapy, the combination of hydralazine and isosorbide dinitrate is recommended (COR I, LOE A) to further reduce morbidity and mortality \[[@CR2]\]. Although loop diuretics have not been shown to reduce mortality, they may be initiated in patients with NYHA class II--IV to reduce volume overload (COR I, LOE C) \[[@CR2]\].

Digoxin is a third-line treatment for HF, usually restricted as an add-on therapy to GDEM (COR IIA, LOE B) in patients with NYHA class III or IV HFrEF who remain symptomatic, to reduce the risk of hospitalization \[[@CR2]\]. In addition, digoxin is often used in patients with atrial fibrillation to achieve rate control as an adjunct to beta-blockers \[[@CR2]\]. However, physicians should be aware that digoxin toxicity may occur (1) with high doses (0.375--0.50 mg daily) \[[@CR32], [@CR33]\]; (2) in patients with coexisting hypokalemia, hypomagnesemia, or hypothyroidism \[[@CR34], [@CR35]\]; and (3) with the concomitant use of drugs that increase digoxin serum concentrations \[[@CR36]--[@CR38]\]. To prevent toxicity, concomitant drug interactions and comorbidities should be considered upon digoxin initiation, and patients should be continually monitored \[[@CR2], [@CR39]\].

Two types of devices are available for patients with stage C HFrEF \[[@CR2]\]. Implantable cardioverter-defibrillator (ICD) therapy is recommended (COR I, LOE A) for the primary prevention of sudden cardiac death in patients with NYHA class II--III HFrEF receiving GDEM who have either ischemic cardiomyopathy at least 40 days postmyocardial infarction or nonischemic dilated cardiomyopathy and a life expectancy over 1 year \[[@CR2]\]. Cardiac resynchronization therapy (CRT) is recommended for NYHA class II, III, or ambulatory NYHA class IV HFrEF (COR I, LOE A for NYHA class III/IV; LOE B for NYHA class II) patients receiving GDEM who are in sinus rhythm with a left bundle-branch block and a QRS duration of ≥ 150 ms \[[@CR2]\].

Stage D patients have advanced end-stage refractory HF and remain persistently symptomatic despite maximum pharmacological and device therapies \[[@CR2]\]. These patients need to be referred to advanced HF centers for specialized treatment strategies, such as insertion of mechanical circulatory assist devices and consideration of cardiac transplantation or end-of-life care \[[@CR2]\].

Many of the medications commonly prescribed in patients with HF, including antiarrhythmic drugs, nonsteroidal anti-inflammatory drugs, and thiazolidinediones, have been shown to potentially worsen HF \[[@CR2]\]. These should be avoided and discontinued whenever possible (COR III, LOE B) \[[@CR2]\]. Calcium channel-blocking drugs (other than amlodipine and felodipine) should not be used to treat patients with HFrEF (COR III, LOE A) because they may worsen outcomes for these patients \[[@CR40]--[@CR44]\]. Additionally, the long-term use of infused positive inotropic drugs should be avoided in patients with HFrEF, except when used as palliation (COR III, LOE C), because they may worsen HF or precipitate death \[[@CR2]\].

Although GDEM improves patient outcomes, physician adherence to clinical practice guideline recommendations is suboptimal \[[@CR45]\]. For example, renin-angiotensin-aldosterone system (RAAS) blockers are recommended to reduce the risk of mortality and hospitalization in patients with HF \[[@CR2]\], but these drugs are underutilized \[[@CR45]\]. Optimal implementation of GDEM has the potential to prevent thousands of deaths each year based on estimates from Fonarow and colleagues (Table [1](#Tab1){ref-type="table"}) \[[@CR45], [@CR46]\].Table 1Estimated potential impact of optimal implementation of GDEM \[[@CR45], [@CR46]\]Pharmacologic class of GDEMCurrent HF population eligible for therapy and untreated^a^Potential deaths prevented per year with optimal implementation of therapy^a^ACEI/ARB \[[@CR45]\]501,767 (20.4)6516 (9.6)Beta-blocker \[[@CR45]\]361,809 (14.4)12,922 (19)Aldosterone antagonist \[[@CR45]\]385,326 (63.9)21,407 (31.5)Hydralazine/nitrate \[[@CR45]\]139,749 (92.7)6655 (9.8)CRT \[[@CR45]\]199,604 (61.2)8317 (12.2)ICD \[[@CR45]\]852,512 (49.4)12,179 (17.9)ARNI \[[@CR46]\]2,287,296 (eligible^b^)28,484*ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *ARNI* angiotensin receptor--neprilysin inhibitor, *CRT* cardiac resynchronization therapy, *GDEM* guideline-directed evaluation and management, *HF* heart failure, *HFrEF* heart failure with reduced ejection fraction, *ICD* implantable cardioverter defibrillator^a^Data are presented as *n* (%). Estimates are based on the number of patients with HFrEF in the USA (drawn from the 2010 American Heart Association Heart Disease and Stroke Statistics Update) and the number of patients with HFrEF who are potentially eligible for each of the guideline-recommended HF therapies (drawn from published HF registries)^b^Estimated number of patients with HFrEF who are eligible for ARNI therapy

Patient Monitoring and Management of Fluid Retention {#Sec3}
----------------------------------------------------

At each patient encounter, vital signs and volume status should be evaluated, including patient weight, jugular venous pressure, peripheral edema, and orthopnea (COR I, LOE B) \[[@CR2]\]. For patients with HFrEF who have evidence of fluid retention, diuretic therapy is recommended in addition to GDEM for symptomatic management, unless contraindicated (COR I, LOE C) \[[@CR2]\]. Loop diuretics should be initiated at low doses and uptitrated until weight decreases by 0.5--1.0 kg daily \[[@CR2]\]. Twice-daily administration may be employed to sustain these effects, if necessary. For patients who are resistant to diuretics, intravenous administration or combination with different diuretic classes may be considered \[[@CR2]\].

Because of the risk for electrolyte disturbances, azotemia, and hypotension with diuretics, aldosterone antagonists, ACEIs, and ARBs, it is recommended that renal function and serum electrolytes should be monitored within 2 weeks of initiating or modifying therapy and periodically thereafter (COR I, LOE C) \[[@CR2]\]. Serial measurement of natriuretic peptide concentrations for the purpose of improving patient outcomes is not recommended because supporting evidence is lacking \[[@CR47]\].

Subclinical Progression in Stable HF {#Sec4}
------------------------------------

Patients with stable HF typically experience subtle disease progression that is often not clinically detectable. Even when patients are receiving GDEM, considerable cardiac damage and progression of HF can occur over time as a result of continued deleterious effects of activated RAAS and sympathetic nervous system pathways as well as inadequate effects of endogenous compensatory peptides (e.g., natriuretic peptides, bradykinin) \[[@CR48]\]. For example, many patients with clinically stable HF have elevated cardiac troponin T concentrations, suggesting continuous underlying cardiac myocyte injury \[[@CR49]\]. Elevated troponin concentrations in patients with stable HF are associated with increased risk of cardiovascular mortality and morbidity \[[@CR49], [@CR50]\]. Disease progression can also occur as a result of prolonged endothelial dysfunction and alterations in the nitric oxide pathway, which promote increased vascular stiffness, myocardial damage, and vascular remodeling \[[@CR51]\].

Table [2](#Tab2){ref-type="table"} summarizes some clinical characteristics of patients with advanced HF that indicate *clinically* obvious disease progression \[[@CR2]\]. For example, weight loss without other causes may indicate cardiac cachexia, which is associated with poor prognosis \[[@CR52]\]. Although these features of disease progression are often clear in patients with advanced HF, predicting which *clinically stable* patients may decompensate is challenging. This difficulty is highlighted by studies such as PARADIGM-HF (Prospective Comparison of ARNI (angiotensin receptor--neprilysin inhibitor) with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure; NCT01035255), in which 26.5% of patients with apparently stable HF who received standard-of-care therapy, including enalapril, experienced a primary event of cardiovascular death or first hospitalization for worsening HF (WHF) during the trial (median duration of follow-up, 27 months) \[[@CR53]\]. Indeed, no simple means exist for physicians to predict when a seemingly stable patient will decompensate. Thus, it is important for physicians to remain aware of the significant risks associated with all stages of HF and to recognize therapies that may improve the underlying pathophysiology of HF for patients with stable yet progressive disease.Table 2Characteristics of patients with advanced HF \[[@CR2]\]Repeated (≥ 2) hospitalizations or emergency department visits for HF in the past yearProgressive deterioration in renal functionWeight loss without other causeIntolerance to ACEIs due to hypotension and/or worsening renal functionIntolerance to beta-blockers due to worsening HF or hypotensionFrequent systolic blood pressure of \< 90 mmHgPersistent dyspnea with dressing or bathing, requiring restInability to walk one block on level ground due to dyspnea or fatigueRecent need to escalate diuretics to maintain volume status, often reaching daily furosemide-equivalent dose of \> 160 mg/day and/or use of supplemental metolazone therapyProgressive decline in serum sodium, usually to \< 133 mEq/lFrequent implantable cardioverter-defibrillator shocks*ACEI* angiotensin-converting enzyme inhibitor, *HF* heart failure

Potential Impact of New Therapies {#Sec5}
=================================

Two new therapies have the potential to improve outcomes for patients with stable, symptomatic HF \[[@CR47]\]. In April 2015, ivabradine became the first new medication in nearly a decade to be approved by the US FDA for the treatment of chronic HF \[[@CR54]\]; in July 2015, the FDA also approved the ARNI sacubitril/valsartan for the same condition \[[@CR55]\].

Ivabradine {#Sec6}
----------

Ivabradine is a specific inhibitor of the hyperpolarization-activated cyclic nucleotide-gated channel, which is responsible for diastolic depolarization of pacemaker cells in the sinoatrial node \[[@CR56]\]. Ivabradine is therefore a pure heart-rate--reducing agent with no other cardiovascular effects, indicated to reduce the risk of hospitalization for WHF \[[@CR56]\]. The approval of ivabradine was based on results of the randomized, double-blind SHIFT (Systolic Heart Failure Treatment With the *I*~f~ Inhibitor Ivabradine Trial; NCT02441218) that compared ivabradine versus placebo in 6558 patients with symptomatic HFrEF \[[@CR56], [@CR57]\]. Eligible patients were required to have stable, symptomatic HF with a baseline EF of ≤ 35%; to be in sinus rhythm with a resting heart rate of at least 70 beats per minute (bpm); to have been hospitalized for HF within the last year; and to be receiving stable background treatment, including a beta-blocker, at the maximally tolerated dose or have a contraindication to beta-blocker use \[[@CR56], [@CR57]\]. Over a median follow-up period of 22.9 months, significantly fewer patients in the ivabradine group \[793/3268 (24%)\] than in the placebo group \[937/3290 (29%)\] experienced the primary endpoint of cardiovascular death or hospitalization for WHF (HR 0.82; 95% CI 0.75--0.90; *P *\< 0.001) \[[@CR57]\]. The effects were primarily driven by hospital admissions for WHF \[672 (21%) placebo vs. 514 (16%) ivabradine; HR 0.74; 95% CI 0.66--0.83; *P *\< 0.0001\] and deaths due to HF \[151 (5%) vs. 113 (3%); HR 0.74; 95% CI 0.58--0.94; *P *= 0.014\] \[[@CR57]\]. Overall, findings from SHIFT indicated that heart rate reduction has the potential to improve clinical outcomes for patients with stable, chronic HF \[[@CR57]\]. However, ivabradine has been shown to increase the risk of atrial fibrillation \[[@CR56], [@CR57]\]. It should be used only in patients with normal sinus rhythm and discontinued if patients develop atrial fibrillation \[[@CR56], [@CR57]\].

Sacubitril/Valsartan {#Sec7}
--------------------

Sacubitril/valsartan is a novel, first-in-class drug that combines a neprilysin inhibitor with an ARB \[[@CR58], [@CR59]\]. Sacubitril is a prodrug that is metabolized to LBQ657, which inhibits neprilysin endopeptidase. Neprilysin inhibition prevents the degradation of B-type natriuretic peptide (BNP) and other compensatory peptides (e.g., bradykinin, adrenomedullin), thus increasing plasma levels of these peptides and enhancing their beneficial effects, which include vasodilation, natriuresis, diuresis, and inhibition of pathogenic growth and fibrosis \[[@CR58], [@CR59]\]. Valsartan counterbalances the increase of angiotensin II that also results from neprilysin inhibition, while simultaneously exerting the beneficial effects of ARBs seen in previous HF trials \[[@CR60]\]. Unlike previous neprilysin inhibitors, such as omapatrilat, ARNI therapy does not inhibit angiotensin-converting enzyme, which allows for the degradation of bradykinin and thus lowers the risk for angioedema \[[@CR60]\].

In the PARADIGM-HF trial, the safety and efficacy of sacubitril/valsartan were compared with that of enalapril, the standard-of-care ACEI shown to reduce mortality in patients with chronic HFrEF \[[@CR53], [@CR59]\]. The mean dose (18.9 mg/day) of enalapril used in this trial was the highest dose achieved in any of the large outcome trials \[[@CR53]\]. This randomized, double-blind, phase III trial enrolled 8442 patients with stable HFrEF (EF ≤ 40%) and NYHA class II, III, or IV functional status who were receiving adequate doses of current standard-of-care HF medications, including an ACEI or ARB, beta-blockers, and mineralocorticoid antagonists \[[@CR53]\]. Patients were randomly assigned 1:1 to receive enalapril 10 mg twice daily or sacubitril/valsartan 200 mg twice daily in addition to comprehensive concomitant background HF therapy. Patients were followed for a median of 27 months. Evaluation of the primary endpoint showed that, compared with enalapril, use of sacubitril/valsartan was associated with a 20% reduction in the composite of cardiovascular death or first hospitalization for HF (HR 0.80; 95% CI 0.73--0.87; *P *\< 0.001), a 16% reduction in death from any cause (HR 0.84; 95% CI 0.76--0.93; *P *\< 0.001), and significant improvements in HF symptoms and physical limitations as measured by the Kansas City Cardiomyopathy Questionnaire (between-group difference 1.64; 95% CI 0.63--2.65; *P *= 0.001) \[[@CR53]\]. Additionally, sudden cardiac death was significantly reduced with sacubitril/valsartan compared with enalapril (HR 0.80; 95% CI 0.68--0.94; *P *= 0.008) \[[@CR61]\]. Sacubitril/valsartan was generally well tolerated; the adverse events hypotension and nonserious angioedema were more common with sacubitril/valsartan, whereas renal impairment, hyperkalemia, and cough were more common with enalapril \[[@CR53]\]. Significantly fewer patients in the sacubitril/valsartan group stopped treatment because of renal impairment compared with the enalapril group (0.7 vs. 1.4%; *P *= 0.002) \[[@CR53]\].

As mentioned, one in four patients in the control group of PARADIGM-HF trial receiving GDEM had a primary clinical event (cardiovascular death or HF hospitalization) \[[@CR53]\]. Thus, these apparently stable patients receiving adequate treatment remained at a high risk for serious adverse clinical outcomes. The benefit of sacubitril/valsartan was observed in these stable patients (75% of patients randomized to treatment had NYHA class I or II functional status). The beneficial effects of sacubitril/valsartan compared with enalapril were consistent across all subgroups, regardless of patient baseline demographics and clinical characteristics \[e.g., age, sex, ethnicity, geographic region, NYHA class, comorbidities, EF, N-terminal pro-BNP (NT-proBNP) level, HF treatment history, or hospitalization history\] \[[@CR53]\]. Moreover, a recent analysis showed that optimal implementation of ARNI therapy in the appropriate community-based population of patients with NHYA class II--III HFrEF who tolerate ACEI/ARB therapy would prevent approximately 28,000 deaths per year \[[@CR46]\].

A separate analysis of data from the PARADIGM-HF trial performed in surviving patients showed that those who received sacubitril/valsartan were significantly less likely to require intensification of HF treatment (*P *= 0.003) or emergency-department treatment for WHF (*P *= 0.001) than patients who received enalapril \[[@CR62]\]. Patients treated with sacubitril/valsartan were also less likely to have WHF requiring the addition of a new drug, intravenous therapy, or an increase in the daily dose of diuretic for \> 1 month (*P *= 0.003); to be evaluated and treated for WHF in the emergency department but discharged without hospital admission (*P *= 0.001); to be hospitalized for WHF (*P *\< 0.001); to be hospitalized for any reason (*P* \< 0.001); to be hospitalized for HF more than once (*P *= 0.001); to receive intravenous inotropic agents (*P *\< 0.001); to require intensive care (*P *= 0.019); or to require HF device implantation or heart transplantation (*P *= 0.07) \[[@CR62]\]. In these patients, sacubitril/valsartan treatment was associated with lower levels of NT-proBNP and troponin, which are biomarkers for myocardial wall stress and injury, than was enalapril \[[@CR62]\].

Guideline Update {#Sec8}
----------------

The remarkable results of the SHIFT and PARADIGM-HF trials led the ACC/AHA/Heart Failure Society of America (HFSA) to release an update to the guideline for the management of HF in May 2016 \[[@CR4]\]. The recommendations provided in the 2016 guideline update have been carried over to the most recent 2017 guideline update \[[@CR47]\]. The guideline recommended that ivabradine "can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II, III) stable chronic HFrEF (LVEF ≤ 35%) who are receiving GDEM, including a beta-blocker at the maximum-tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest" (COR IIA, LOE B--R) \[[@CR4], [@CR47]\]. The update noted that only 25% of patients in the trial were receiving optimal doses of beta-blocker therapy and encouraged efforts to maximize the use of these agents in this setting. The second specific recommendation in the update related to the ARNI class of drugs, of which only sacubitril/valsartan is currently available and approved \[[@CR4], [@CR47]\]. The update added the ARNI class to an existing recommendation (alongside ACEIs or ARBs) for a management strategy to reduce morbidity and mortality in patients with chronic HFrEF (COR I, LOE B--R) \[[@CR4], [@CR47]\]. It specifically noted that patients with chronic, symptomatic HFrEF who have NYHA class II or III disease should be *switched* from an ACEI or ARB to the ARNI, sacubitril/valsartan, to further reduce morbidity and mortality (COR I, LOE B--R) \[[@CR46], [@CR47]\]. This particular recommendation represents a clear departure from the previous guideline that only recommended adding newly approved drugs to existing standard-of-care therapy and never recommended switching one class of therapy for another.

It is important to point out that the American Academy of Family Physicians (AAFP) has not completely endorsed these guideline recommendations because of concerns that sacubitril/valsartan was tested only in one study and that postmarketing data in the American population on potential harm and adverse side effects are limited \[[@CR63]\]. However, it should be emphasized that the patients enrolled in the PARADIGM-HF trial from the USA were typical of patients seen in primary care practice: Approximately 26% were African American and nearly 60% had an ICD \[[@CR64]\]. In patients from the USA, a somewhat greater beneficial effect with sacubitril/valsartan compared with enalapril on the primary outcome was observed (HR 0.66; 95% CI 0.47--0.92) compared with that of the entire cohort (HR 0.80; 95% CI 0.73--0.87) \[[@CR64]\]. Similar patient characteristics and outcomes were observed in the prespecified subgroup analyses for North America (including both Canada and the USA); 54% of these patients had an ICD, 19% were Black, and a somewhat greater beneficial effect with sacubitril/valsartan compared with enalapril on the primary outcome was observed (HR 0.67; 95% CI 0.50--0.90) compared with that of the entire cohort (HR 0.80; 95% CI 0.73--0.87) sacubitril/valsartan \[[@CR65]\]. Because the evidence for the 20% reduction in the primary endpoint (*P* \< 0.001) and for the 20% lower risk of cardiovascular death (*P* \< 0.001) with sacubitril/valsartan compared with enalapril was very strong \[[@CR53]\], randomizing patients to treatment with enalapril to replicate PARADIGM-HF trial results would not be ethical \[[@CR64]\].

In PARADIGM-HF, sacubitril/valsartan was very well tolerated, and fewer patients taking sacubitril/valsartan discontinued study medication because of adverse effects compared with those taking enalapril \[[@CR53]\]. Hypotension that required dose reduction was seen more often with sacubitril/valsartan, but renal dysfunction, hyperkalemia, and cough requiring discontinuation of study medication were more common with enalapril \[[@CR66]\]. Few cases of angioedema were reported, with no significant difference between study groups \[[@CR53]\]. Furthermore, in a meta-analysis of six hypertension and HF trials involving 11,821 patients, sacubitril/valsartan was associated with significantly lower risk of treatment discontinuation for any adverse event than was an ACEI/ARB or placebo \[[@CR67]\]. Therefore, based on a critical examination of the available literature on sacubitril/valsartan, it is difficult to understand the reluctance of the AAFP to fully endorse the AHA/ACC/HFSA guideline recommendations to replace ACEI or ARB therapy with sacubitril/valsartan in patients with HFrEF.

The guideline update also offers two important safety recommendations with respect to the ARNI class: "ARNI should not be administered concomitantly with ACEIs or within 36 hours of the last dose of an ACEI" (COR III, LOE B--R) and "ARNI should not be administered to patients with a history of angioedema" (COR III, LOE C--EO) \[[@CR4], [@CR47]\]. These safety recommendations address the potential risk for angioedema that was observed with omapatrilat (a dual neprilysin inhibitor/ACEI), which halted the clinical development of this drug \[[@CR60], [@CR68]\]. The higher incidence of angioedema was because both pharmacodynamic effects of omapatrilat result in bradykinin accumulation. Because ARBs do not inhibit bradykinin degradation, the substitution of an ARB agent (such as valsartan) for the ACEI should mitigate the risk for angioedema. Indeed, the overall incidence of angioedema in the PARADIGM-HF trial was low and nonsignificant compared with enalapril (19 vs. 10; *P *= 0.13) \[[@CR53]\]. It is also important to note that because one component of ARNI therapy is an ARB agent (i.e., valsartan in sacubitril/valsartan), ARNI should also not be used concomitantly with another ARB \[[@CR69]\].

Areas for Improvement in the Treatment of HF {#Sec9}
============================================

Uptitration of Pharmacologic Therapies {#Sec10}
--------------------------------------

The ACCF/AHA guideline for the management of HF recommends uptitration of GDEM to the target or highest-tolerated doses (Table [3](#Tab3){ref-type="table"}) shown to improve outcomes in clinical trials \[[@CR2]\]. Optimized GDEM for stage C HFrEF decreased the relative risk of mortality by 17--43% and the relative risk of HF hospitalization by 31--41% against the comparator arms in randomized controlled trials \[[@CR2]\]. However, HF medication doses are not always escalated as directed \[[@CR70], [@CR71]\]. There are several possible reasons for this observation. One explanation may be that patients with HF are not seen often enough to allow for adjustments. Some physicians perceive that escalated doses of HF drugs may negatively affect patients or higher doses of ACEIs, ARBs, and aldosterone receptor antagonists may worsen renal function \[[@CR2]\]. Thus, physicians may be hesitant to increase doses when renal function cannot be carefully monitored. However, considerable evidence suggests that despite mild worsening of renal function, uptitration of RAAS blockers and aldosterone antagonists is associated with better outcomes \[[@CR72]--[@CR74]\]. The development of hypotension may prevent uptitration due to concerns of advanced pump failure, but other causes of hypotension should be considered before adjusting HF medications. These other causes include overdiuresis, dehydration, acute coronary syndrome, ischemia, arrhythmia, autonomic dysfunction, gastrointestinal bleeding, infection, or use of drugs for conditions other than HF \[[@CR75]\]. Typically, hypotension resolves spontaneously after diuretic dose reduction in euvolemic patients or after management of other medications and/or comorbidities \[[@CR75]\]. Moreover, vasodilators such as RAAS blockers and the combination of hydralazine and isosorbide often improve blood pressure with continued use \[[@CR76], [@CR77]\]. Some physicians are concerned that intensification of beta-blocker therapy may lower cardiac output short term and worsen HF; however, the author is aware of no evidence to date that uptitration of beta-blockers is associated with hospitalization in the subsequent 30 days \[[@CR70]\].Table 3Evidence-based doses of drugs commonly used for the treatment of HF \[[@CR2]\]DrugStarting dose, mgTarget dose, mgACEIs Captopril6.25 tid50 tid Enalapril2.5 bid10--20 bid Fosinopril^a^5--10 od40 od Lisinopril2.5--5.0 od20--40 od Perindopril^a^2 od8--16 od Quinapril^a^5 bid20 bid Ramipril^a^1.25--2.5 od10 od Trandolapril^a^1 od4 odARBs Candesartan4--8 od32 od Losartan25--50 od50--150 od Valsartan20--40 bid160 bidARNI Sacubitril/valsartan100 bid200 bidAldosterone antagonists Eplerenone25 od50 od Spironolactone12.5--25.0 od25 od or bidBeta blockers Bisoprolol1.25 od10 od Carvedilol3.125 bid50 bid Carvedilol CR^a^10 od80 od Metoprolol succinate (CR/XL)12.5--25.0 od200 odHydralazine and isosorbide dinitrate Fixed-dose combination37.5 hydralazine/20 isosorbide dinitrate tid75 hydralazine/40 isosorbide dinitrate tidDoses are presented as mg*ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *ARNI* angiotensin receptor--neprilysin inhibitor, *bid* twice daily, *CR* controlled release, *od* once daily, *tid* three times daily, *XL* extended release^a^Suggested target doses were not studied in clinical trials

Interestingly, evidence suggests that patients having telephone consultations at 1- to 3-week intervals with registered nurses or cardiologists may efficiently optimize dose escalation of HF medication, improving clinical outcomes \[[@CR78]\]. Analysis of data from the Train-the-Trainer trial also found that increasing the self-confidence of PCPs in treating HF by using educational interventions improved evidence-based prescription of RAAS blockers \[[@CR79]\]. However, other studies do not support such interventions \[[@CR80]\], and more studies are required to confirm these findings.

The GUIDE-IT (Guiding Evidence-based Therapy Using Biomarker Intensified Treatment in Heart Failure; NCT01685840) study aimed to assess whether natriuretic peptide (i.e., NT-proBNP)-guided treatment improved clinical outcomes versus usual care in high-risk patients with HFrEF \[[@CR81]\]. The data and safety monitoring board recommended stopping the study when only 894 of the planned 1100 patients had been enrolled, with follow-up for a median of 15 months, because of futility \[[@CR82]\]. The primary outcome of the composite of time-to-first HF hospitalization or death from cardiovascular causes occurred in 164 patients (37%) in the biomarker-guided group and 164 patients (37%) in the usual-care group \[[@CR82]\]. None of the secondary endpoints, nor the decreases in the NT-proBNP levels achieved, differed significantly between groups \[[@CR82]\]. Hence, the natriuretic peptide-guided strategy to uptitrate HF medications cannot be recommended. Additional research is necessary to improve implementation of evidence-based therapy into clinical practice. Meanwhile, physicians are encouraged to optimize guideline-recommended uptitration of HF medications.

Switching Therapies {#Sec11}
-------------------

As mentioned, previous guideline recommendations focused on stacking newer therapies on older approved drugs and have not considered it appropriate to switch a patient's existing pharmacologic regimen \[[@CR83]\]. This is because all previous trials have compared the active drug on top of the standard of care against a placebo \[[@CR84]\]. However, the PARADIGM-HF trial tested the ARNI sacubitril/valsartan against the active comparator ACEI enalapril and found it to be superior \[[@CR84]\]. Hence, the guidelines recommend switching from ACEI/ARB therapy to ARNI therapy \[[@CR47]\].

Unfortunately, physicians are often hesitant to even intensify therapies when patients appear to be stable and lack clinical evidence of progression \[[@CR85]\]. Therefore, physicians may be even more diffident to switch to a new therapy in stable patients. Considerable efforts may be required to educate physicians about the benefits of switching from ACEI/ARB to ARNI therapy. In many cases, physicians may find it easier to implement new HF treatment strategies with new patients than to switch therapy in seemingly stable patients.

When considering a switch in medication, physicians should confirm that patients are receiving therapeutically appropriate doses of their current treatments and that aggressive efforts have been made to reach target doses (Table [3](#Tab3){ref-type="table"}). Analysis of data from the IMPROVE-HF (Registry to Improve the Use of Evidence-based Heart Failure Therapies in the Outpatient Setting; NCT00303979) showed that, prior to implementation of a practice-based performance improvement intervention at outpatient cardiology clinics, only 36.1, 20.5, and 74.4% of patients were receiving recommended target doses of ACEIs/ARBs, beta-blockers, and aldosterone antagonists, respectively \[[@CR86]\]. Similarly, data from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure; NCT00344513) indicated that target doses of the beta-blockers carvedilol and metoprolol succinate, used for 60--90 days after hospital discharge, were achieved only by 17.5 and 7.9% of patients, respectively \[[@CR71]\].

Improving Adherence {#Sec12}
-------------------

Although GDEM is recommended to reduce the risk of disease progression, it is not always appropriately initiated in clinical practice. A survey of 1378 specialists in family medicine, internal medicine, and general cardiology found that referral practices for an ICD for primary prevention are often discordant with evidence-based guideline recommendations from the ACC/AHA/Heart Rhythm Society \[[@CR83]\]. Survey results observed that 28% of respondents reported that they never refer patients for consideration of an ICD, 15% believed ventricular arrhythmia is required before an ICD is indicated, and 36% believed an EF \> 40% warrants an ICD \[[@CR83]\]. Of the respondents, the specialists most likely to give responses that were inconsistent with guideline recommendations were family practice physicians, as demonstrated by multivariate analyses of survey responses \[[@CR83]\].

Similarly, telephone interviews with clinicians at US Department of Veterans Affairs healthcare systems found that many physicians believe HF guideline recommendations are less applicable in the very elderly (aged \> 80 years) and in those with multiple comorbidities that increase clinical complexity and risk of adverse medication effects \[[@CR87]\]. Practitioners reported having concerns about the validity of evidence-based HF guideline recommendations in these higher-risk patient populations, despite evidence that these subgroups may receive greater absolute benefit from HF medications \[[@CR87]\]. Correspondingly, findings from the HART (Heart Failure Adherence Retention Trial) showed that physicians are significantly less likely to follow evidence-based guideline recommendations for ACEIs/ARBs and beta-blockers---which include not prescribing therapy when contraindicated---in patients with multiple comorbidities, older patients, patients with higher NYHA class, and ethnic minorities \[[@CR88]\].

HF Management in Primary Care {#Sec13}
-----------------------------

The quality of the PCP--patient relationship is essential for the optimal management of HF. To reduce the risk of poor outcomes, physicians must be able to identify the often-subtle symptoms of WHF in seemingly stable patients \[[@CR89]\]. Thus, physicians need to establish a trusting relationship with patients to whom they provide information about the progressive nature of HF along with reassurances to alleviate patient fears and concerns. Patients should feel comfortable having honest conversations with their PCPs and should feel confident that their providers are knowledgeable about HF. However, a recent study by Zickmund et al. \[[@CR89]\] found that about three in ten patients expressed complaints about their physicians, including poor interpersonal skills, lack of confidence in their medical competence to diagnosis and treat congestive HF, and inability to provide sufficient medical information. Therefore, initiatives are needed to train physicians in ways to improve the PCP--patient relationship \[[@CR89]\]. To improve patient confidence, physicians should have strong knowledge of current HF guideline recommendations and stay abreast of new therapies and strategies to improve patient care.

PCPs should also collaborate with other healthcare professionals as part of a multidisciplinary network of care because team approaches that include input from cardiologists, nurses, pharmacists, physical therapists, dietitians, and PCPs have been shown to improve patient survival, decrease readmission rates, and improve patient quality of life \[[@CR90], [@CR91]\]. For example, Lee et al. \[[@CR92]\] found that collaboration between a PCP and a cardiologist within 30 days of a patient's hospital discharge improved rates of follow-up testing, use of GDEM, and survival compared with PCP care alone. Moreover, multidisciplinary HF disease-management programs are recommended to facilitate the implementation of GDEM, prevent readmissions to hospital, and address barriers to behavior change (COR I, LOE B) \[[@CR2]\].

Conclusions {#Sec14}
===========

Although HF management has considerably improved in the past several years, mortality rates remain high, with only about 50% of patients surviving more than 5 years after diagnosis \[[@CR7]\]. Fortunately, recent clinical studies of ivabradine and sacubitril/valsartan suggest that, for the first time in more than a decade, patient outcomes for HF could be further improved. These new therapies were tested in patients with apparently stable HF, who often experience subclinical disease progression in the absence of symptoms or signs of decompensation. Data from these trials underscore the fact that the apparently stable patient with chronic HF remains at increased risk of asymptomatic progression of HF, death, and hospitalization. However, we now have new therapies that have been shown to be particularly beneficial for such patients.

In conclusion, physicians need to stay informed about advances in HF treatment and strive to improve HF management strategies for their patients. Early therapeutic intervention with aggressive uptitration of GDEM is important to reduce poor outcomes, and new therapies are likely to prevent disease progression. Physicians must also stay engaged with patients to identify subtle signs of disease progression and maintain an open dialogue with patients to ensure their needs are being met.
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